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A structural and biochemical 
comparison of Ribonuclease e 
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Darren M. Gowers1, Helen s. Atkins2,3,4, Helen A. Vincent1 & Anastasia J. Callaghan1
Regulation of gene expression through processing and turnover of RNA is a key mechanism that 
allows bacteria to rapidly adapt to changing environmental conditions. Consequently, RNA degrading 
enzymes (ribonucleases; RNases) such as the endoribonuclease RNase e, frequently play critical roles 
in pathogenic bacterial virulence and are potential antibacterial targets. RNase e consists of a highly 
conserved catalytic domain and a variable non-catalytic domain that functions as the structural scaffold 
for the multienzyme degradosome complex. Despite conservation of the catalytic domain, a recent 
study identified differences in the response of RNase E homologues from different species to the same 
inhibitory compound(s). While RNase e from Escherichia coli has been well-characterised, far less is 
known about RNase e homologues from other bacterial species. In this study, we structurally and 
biochemically characterise the RNase e catalytic domains from four pathogenic bacteria: Yersinia pestis, 
Francisella tularensis, Burkholderia pseudomallei and Acinetobacter baumannii, with a view to exploiting 
RNase e as an antibacterial target. Bioinformatics, small-angle x-ray scattering and biochemical 
RNA cleavage assays reveal globally similar structural and catalytic properties. surprisingly, subtle 
species-specific differences in both structure and substrate specificity were also identified that may be 
important for the development of effective antibacterial drugs targeting RNase E.
For survival, microorganisms must have the ability to rapidly adapt to environmental changes. One mechanism 
for achieving this is regulation of gene expression through the differential processing and/or turnover of RNAs by 
ribonucleases (RNases)1. The importance of RNases in these processes is underlined by the roles that they play in 
pathogenic bacterial virulence2 and, as a consequence, RNases are emerging as attractive antibacterial drug tar-
gets2–4. For example, the endoribonuclease RNase E is essential for cell viability in Escherichia coli5–7 where roles 
in mRNA decay and the maturation of tRNA and rRNA have been well documented [reviewed in1 and8]. RNase 
E is also required for cell viability in Salmonella enterica9 and has been implicated in the pathogenicity of both S. 
enterica and Yersinia pestis10,11. Furthermore, since homologues of RNase E are predicted to be present in many 
bacteria12, including pathogenic species, but are not found in animals or humans, RNase E is an ideal potential 
antibacterial target2–4,13.
E. coli RNase E (EcRNase E) is the founding member of Type I RNase Es, found in betaproteobacteria, 
gammaproteobacteria and cyanobacteria12,14, and has been extensively characterised. It is a large protein con-
taining 1061 amino acids and can be divided into two domains. The N-terminal domain (NTD) is responsi-
ble for the endoribonuclease activity15 and the C-terminal domain (CTD) forms the structural scaffold for the 
RNA-degrading multienzyme complex, the degradosome16,17. The catalytic NTD consists of five subdomains: 
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an RNase H domain, an S1 domain, a 5′ sensor, a deoxyribonuclease (DNase) I domain and a small domain18 
(Supplementary Fig. S1). It is a homotetramer formed by interactions between small domains18–21. The catalytic 
site is located in the DNase I domain and harbours a hydrated magnesium ion, coordinated by two aspartic 
acids, Asp303, positioned by asparagine Asn305, and Asp346, that is essential for the hydrolytic cleavage of the RNA 
substrate18. EcRNase E cleaves single-stranded A/U-rich regions22 and has a strong preference for a 5′ monophos-
phate23. Specificity for a uracil at the +2 position relative to the cleavage site is defined by the uracil pocket 
in the S1 domain24. This pocket is comprised of Phe67, positioned by Phe57, and the Lys112-Gly113-Ala114-Ala115 
(KGAA) loop24. In addition, recognition of a 5′ monophosphorylated substrate requires the 5′ sensor pocket, 
formed by amino acids Gly124, Val128, Arg141, Arg142, Arg169, Thr170 and Arg373 with Val128, Arg169 and Thr170 playing 
the critical roles in 5′ monophosphate detection18,25. Binding of the RNA substrate by the 5′ sensor is predicted 
to induce a significant structural conformational change that helps to correctly position the RNA substrate for 
cleavage26.
A number of RNase E homologues from other species have been partially characterised [reviewed in12]. In 
general, the sequence of the catalytic region of RNase E is highly conserved, whereas the sequence of the degra-
dosome scaffold region is more variable12. Consequently, the focus has mostly been on the degradosome scaf-
fold and its interacting partners12. However, there are indications that the properties of the catalytic domain are 
species-specific27 and that species-specific differences can extend to the response to potential antibacterial com-
pounds shown to inhibit EcRNase E13. Therefore, characterising the properties of the RNase E catalytic domain 
from a variety of species may be critical for the development of effective antibacterial drugs targeting RNase 
E. In this study, we have characterised the structural and biochemical properties of the catalytic domain of the 
RNase E homologue from four bacterial pathogens, chosen because of their importance in both the health and 
defence sectors. Specifically, RNase E homologues were chosen from bubonic plague causing Y. pestis (YpRNase 
E), tularemia causing Francisella tularensis (FtRNase E), melioidosis causing Burkholderia pseudomallei (BpRNase 
E) and ESKAPE pathogen28 Acinetobacter baumannii (AbRNase E). The sequence and structure of the RNase E 
catalytic domains were initially investigated in silico, before comparing their low-resolution solution structures to 
that of EcRNase E by small-angle x-ray scattering (SAXS). The substrate specificity was also compared to that of 
EcRNase E using biochemical assays. Collectively, these studies have revealed subtle species-specific differences in 
the properties of previously uncharacterised RNase E catalytic domains from pathogenic species that may prove 
to be important for the development of effective antibacterial compounds targeting RNase E.
Results
sequence analysis of RNase e NtDs. In order to compare the protein sequences of the RNase E homo-
logues from the gammaproteobacteria E. coli, Y. pestis, F. tularensis, and A. baumannii and betaproteobacteria 
B. pseudomallei a multiple sequence alignment of the five full-length proteins was generated and trimmed to 
the boundaries of the EcRNase E NTD (Fig. 1). As expected, based on their phylogeny, YpRNase, FtRNase E, 
AbRNase and BpRNase E all belong to the Type I class of RNase Es with catalytic domains of a similar length to 
EcRNase E NTD located at the N-terminus of the protein. Consequently, from this point forwards, we will also 
refer to these catalytic domains as NTDs. The alignment reveals that the amino acid sequence of the NTD is 
highly conserved, with similarities of 69.4% for FtRNase E, 70.5% for AbRNase E, 75.4% for BpRNase E and 96% 
for YpRNase E, relative to EcRNase. Furthermore, for these five sequences, there is complete conservation of the 
key residues known to be critical for the specific recognition of substrates containing a 5′ monophosphate by the 
5′ sensor pocket (Val128, Arg169 and Thr170, using numbering for EcRNase E;18,25) and for substrate cleavage at the 
active site (Asp303, Asn305 and Asp346, using numbering for EcRNase E;18) (Fig. 1).
In silico structural analysis of the RNase e NtDs. In order to begin to investigate whether the amino 
acid sequence similarity also correlates with structural similarity, we decided to generate homology models for 
YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs using available EcRNase E NTD crystal structures as 
templates. The crystal structure of EcRNase E NTD has been solved in the presence18,25 and absence26 of RNA 
substrates and collectively these structures suggest a large conformational change between an open and closed 
conformation upon substrate binding26. Both open and closed conformation homology models were generated 
using the EcRNase E NTD crystal structures 2VMK26 and 2BX218 as the template structure, respectively (Fig. 2). 
Globally, the homology models are very similar to the EcRNase E NTD crystal structures and this is reflected in 
the low root-mean-square deviation (RMSD) obtained for each model compared to the template crystal structure 
(Fig. 2). Even regions that are poorly conserved at the sequence level (e.g. amino acids 175–203 of the 5′ sensor, 
233–263 of the RNase H domain and 457–508 of the small domain (Fig. 1)) are predicted to adopt a similar 
conformation (Fig. 2; Supplementary Fig. 2). The RMSDs for the homology models generated using the closed 
EcRNase E NTD crystal structure 2BX218 as a template are slightly lower than those generated using the open 
EcRNase E NTD structure 2VMK26 as the template. However, this most likely reflects the higher resolution of the 
closed structure (2.85 Å)18 compared to the open structure (3.3 Å)26. Overall, these data suggest that YpRNase E, 
FtRNase E, BpRNase E and AbRNase E NTDs are likely to fold into a similar structure and adopt similar confor-
mations to EcRNase E NTD. This also implies that the conformational change from open to closed proposed for 
EcRNase E26 is, at least theoretically, possible.
Purification of recombinant RNase E NTDs. In order to structurally and functionally characterise 
YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs, and compare their properties to those of EcRNase E 
NTD, pure recombinant RNase E NTDs were produced. An expression plasmid that was previously used for the 
expression, purification and characterisation of an N-terminally His-tagged EcRNase E NTD19,29 was obtained 
from Prof. Ben Luisi, University of Cambridge, UK. We adopted a similar cloning strategy for YpRNase E, 
FtRNase E, BpRNase E and AbRNase E NTDs. All five RNase E NTDs were expressed as N-terminally His-tagged 
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proteins and purified by immobilised Ni2+-affinity chromatography, followed by size-exclusion chromatogra-
phy, as described previously for EcRNase E NTD19. All five RNase E NTDs were successfully purified using this 
approach (Supplementary Fig. S3).
Low-resolution solution structure of RNase e NtDs. The catalytically active form of EcRNase E 
NTD has been shown to be homotetrameric in solution19. During purification, YpRNase E, FtRNase E, BpRNase 
E and AbRNase E NTDs all eluted from the size-exclusion column at a similar volume to EcRNase E NTD 
(Supplementary Table S1), which would be consistent with them also forming homotetramers. In order to fur-
ther investigate, and compare, the structures of the RNase E NTDs, SAXS was employed. SAXS is a technique 
that is able to provide low resolution structural information about the size and shape of proteins in solution30. 
Parameters including molecular weight, radius of gyration (Rg), which indicates the overall size of the protein, 
and maximum particle dimension (Dmax) can be derived from the scattering data, along with information about 
protein flexibility30. The scattering data for the RNase E NTDs are presented in Fig. 3a. Molecular masses were 
estimated from the SAXS profiles (Supplementary Table S1) and are consistent with each protein forming a 
tetramer in solution. For each RNase E NTD, the Rg was determined from Guinier analysis (Fig. 3aii). Rgs ranged 
from 48 to 51 Å, indicating that all five RNase E NTDs are a similar overall size. The Dmax was determined from 
the pair distance distribution (p(R)) plot (Fig. 3b), a plot of the distances between all possible pairs of atoms 
within the protien30, and ranged from 149 to 183 Å, suggesting some variability in the degree of extension of the 
proteins. Finally, dimensionless Kratky plots were used to assess the folding state and flexibility of the proteins30. 
The Kratky plots (Fig. 3c) were similar for each RNase E NTD and had the characteristic multiple bell-shaped 
profile of a multi-domain globular protein.
Ab initio models for EcRNase E NTD were generated based on the SAXS data and were compared to three 
available EcRNase E NTD crystal structures, 2BX2 (closed conformation)18, 2VMK (open conformation)26 and 
5F6C (a transitioning conformation)25 (Supplementary Fig. S4a). None of the crystal structures could be fit-
ted entirely within the average molecular envelope. The experimental scattering data for EcRNase E NTD was 
also compared to theoretical scattering data for the three crystal structures (Supplementary Fig. S4b). We com-
pared the resulting χ2 values to evaluate which of the crystallised conformations the solution scattering data 
most closely resembles. For EcRNase E NTD, the data are most consistent with the transitioning conformation 
(Supplementary Table 2; Supplementary Fig. S4b). A similar comparison of the experimental scattering data for 
YpRNase E, FtRNase E, BpRNase E and AbRNase E NTDs to the theoretical scattering data for the three EcRNase 
E crystal structures was also performed. This revealed that, in solution, YpRNase E, FtRNase E and AbRNase E 
Figure 1. Multiple protein sequence alignment of RNase E catalytic domains. A multiple protein sequence 
alignment of RNase E homologues from E. coli, Y. pestis., F. tularensis, B. pseudomallei and A. baumannii. The 
region corresponding to the catalytic domain is shown and is coloured in accordance with amino acid side chain 
using a heatmap based on a BLOSUM62 matrix. Coloured bars below the alignment indicate the subdomains 
within the catalytic domain of E. coli RNase E (see Supplementary Fig. S1 for a structural representation). The 
alignment numbering is based on E. coli RNase E. Key amino acids forming the 5′ sensor pocket and active 
site18,25 are denoted with white and black triangles, respectively.
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also most closely resemble the transitioning EcRNase E NTD conformation (Supplementary Table S2). In con-
trast, BpRNase E most closely resembles the closed EcRNase E NTD conformation (Supplementary Table S2).
endoribonuclease Activity of RNase e NtDs. Having established that EcRNase E, YpRNase E, FtRNase 
E, BpRNase E and AbRNase E NTDs are all homotetramers that adopt similar global conformations in solution, 
we next wanted to investigate their catalytic properties. We decided to assess the endoribonuclease activity of each 
of the RNase E NTDs using a model 5′ p-RNA13-FAM-3′ substrate in a discontinuous end-point assay (Fig. 4). 
RNA13 has the same nucleotide sequence as the 13-mer oligoribonucleotide that was crystallised in complex with 
EcRNase E NTD18 and is based on a known EcRNase E cleavage site within RNAI from the pBR322 plasmid31. 
Endoribonucleolytic cleavage is expected to occur between the 8th and 9th nucleotide from the 5′ end of the sub-
strate to generate an unlabelled octamer and a 3′ FAM-labelled pentamer (Fig. 4). Both the disappearance of the 
3′ FAM-labelled 13-mer substrate and the appearance of the 3′ FAM-labelled pentamer product can be monitored 
by denaturing polyacrylamide gel electrophoresis (PAGE). As expected, EcRNase E NTD efficiently cleaved this 
substrate such that 95% of the substrate had been degraded at the assay end-point (Fig. 4). YpRNase E, FtRNase E, 
BpRNase E and AbRNase E NTDs also endoribonucleolytically cleaved 5′ p-RNA13-FAM-3′ (Fig. 4). The cleavage 
Figure 2. Homology models of RNase E NTDs. Crystal structures of the closed (2BX2)18 and open (2VMK)26 
conformations of E. coli RNase E NTD (blue ribbons) and homology models of Y. pestis, F. tularensis, B. 
pseudomallei and A. baumannii RNase E NTDs (various coloured ribbons). The Mg2+ ions are shown as 
magenta spheres and the Zn2+ ions are shown as cyan spheres. The averaged homology models have been 
overlaid with the E. coli RNase E NTD crystal structure that was used as the template. The RMSD for each 
homology model in comparison with the template structure is reported in the top left-hand corner of the 
homology model panel.
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Figure 3. SAXS data and analysis for RNase E NTDs. (ai) Radially averaged scattering data for E. coli, Y. pestis., 
F. tularensis, B. pseudomallei and A. baumannii RNase E NTDs. Data have been plotted using an offset for 
visualisation purposes. (aii) Guinier region of the scattering data shown in ai for each of the RNase E NTDs 
together with fits and the derived Rg values. Data have been plotted using an offset for visualisation purposes. 
(b) Distance distribution p(R) plots for each of the RNase E NTDs together with the derived Dmax values. Each 
plot has been normalised to the maximum p(R). (c) Dimensionless Kratky plots for each of the RNase E NTDs.
Figure 4. Cleavage of 5′-p-RNA13-FAM-3′ and 5′-OH-RNA13-FAM-3′ by RNase E NTDs. The sequence of the 
RNA substrates is shown, with an arrow indicating the expected cleavage site. 5 nM E. coli, Y. pestis, F. tularensis, 
B. pseudomallei or A. baumannii RNase E NTD were incubated with 1 μM 5′-p-RNA13-FAM-3′ (p-RNA13) or 
1 μM 5′-OH-RNA13-FAM-3′ (OH-RNA13) at 28 °C for 45 minutes. Reaction products were resolved by 20% 
urea-PAGE and visualised using a G:Box UV transilluminator (Syngene). This figure is assembled from multiple 
gels that have been cropped. The uncropped gels are presented in Supplementary Fig. S5. The percentage of 
cleaved RNA present in each lane is indicated below the gels. Values are an average of three experiments, values 
have been rounded to the nearest whole numbers. Errors, where given, are the standard deviation to the nearest 
whole number (acalculated error was below 0.5).
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efficiency for YpRNase and FtRNase E NTDs was similar to EcRNase E NTD (96% and 93% of the substrate had 
been degraded at the assay end-point, respectively). However, BpRNase E and AbRNase E NTDs both cleaved 5′ 
p-RNA13-FAM-3′ less efficiently than EcRNase E NTD (58% and 88% of the substrate had been degraded at the 
assay end-point, respectively).
Substrate specificity of RNase E NTDs. EcRNase E is known to have a strong preference for substrates 
with a 5′ monophosphate23 (e.g. 5′ p-RNA13-FAM-3′). In order to investigate whether YpRNase E, FtRNase 
E, BpRNase E and AbRNase E NTDs also share this preference we decided to compare the degradation of a 
5′-OH-RNA13-FAM-3′, which has a 5′ hydroxyl, and 5′-p-RNA13-FAM-3′ in the discontinuous end-point assay 
(Fig. 4). As discussed above, EcRNase E NTD efficiently cleaved the 5′-p-RNA13-FAM-3′ substrate with 95% 
substrate degraded at the assay end-point. However, as expected, cleavage of the 5′-OH-RNA13-FAM-3′ substrate 
was relatively inefficient and only 10% of this substrate was degraded by EcRNase E NTD by the assay end-point. 
Similarly, compared to 5′ p-RNA13-FAM-3′, 5′-OH-RNA13-FAM-3′ was a poor substrate for YpRNase E, 
FtRNase E, BpRNase E and AbRNase E NTDs. However, while EcRNase E, YpRNase E, BpRNase E and AbRNase 
E NTDs degraded 10% or less of the 5′-OH-RNA13-FAM-3′ by the assay end-point, FtRNase E NTD cleaved 
25% of this substrate, 2.5-fold more than any of the other RNase E NTDs. Therefore, while all five RNase E NTDs 
display a preference for 5′ monophosphorylated substrates, this preference is less pronounced for FtRNase E.
The short 5′-p-RNA13-FAM-3′ model substrate is cleaved by all of the RNase E NTDs at a specific, single 
site. However, longer, more complex substrates have the potential to be cleaved at multiple sites. For example, a 
partially double-stranded target-guide substrate consisting of a 5′ DABCYL-labelled, 3′ FAM-labelled 27-mer 
and a 5′ phosphorylated 13-mer with partial complementarity to the 5′ end of the 27-mer (Fig. 5ai) is known to 
be cleaved by EcRNase E NTD at multiple sites, each with a different susceptibility to EcRNase E32. Therefore, we 
decided to use the target-guide substrate in a discontinuous assay to compare cleave site specificity of the RNase 
E NTDs. In an initial experiment, 5 nM RNase E NTD was incubated with 1 μM target-guide RNA at 28 °C and 
the cleavage products were analysed by denaturing PAGE after 10 minutes (Fig. 5aii). EcRNase E NTD cleaved the 
27-mer component of the target-guide substrate at five positions: between nucleotides 15 and 16, 16 and 17, 19 
and 20, 22 and 23 and 24 and 25, from the 5′ end, to generate 3′ FAM-labelled cleavage products 12, 11, eight, five 
and three nucleotides in length, respectively. Similar cleavage patterns were observed for YpRNase E, BpRNase 
E and AbRNase E NTDs. Each of these RNase E NTDs also cleaved the 27-mer RNA at the positions cleaved by 
EcRNase E NTD. Although additional cleavage sites were detected between nucleotides 17 and 18 for AbRNase 
E NTD, generating a 3′ FAM-labelled product ten nucleotides in length, and between nucleotides 23 and 24 for 
YpRNase E NTD, generating a 3′ FAM-labelled product four nucleotides in length. The relative predominance of 
the bands representing the common cleavage sites were also similar for EcRNase E, YpRNase E, BpRNase E and 
AbRNase E NTDs. In contrast, FtRNase E NTD displayed a markedly different cleavage pattern to the other four 
RNase E NTDs. In addition to cleaving the 27-mer RNA at the five positions that are cleaved by the other RNase 
E NTDs, FtRNase E NTD also cleaved the 27-mer RNA between nucleotides 18 and 19 and between nucleotides 
21 and 22, generating 3′ FAM-labelled products nine and six nucleotides in length, respectively. Furthermore, the 
relative predominance of the bands representing the common cleavage sites was different for FtRNase E NTD 
relative to the other four RNase E NTDs.
Given the observed similarities and differences in the cleavage patterns of the RNase E NTDs, time-course 
experiments were then used to identify initial cleavage sites and/or preferred cleavage sites (Fig. 5b). For EcRNase 
E NTD, all five cleavage products began to appear from the start of the time-course, consistent with a distribution 
of single cleavage events. The octamer accumulated at the fastest rate, closely followed by the 12- and 11-mers 
suggesting that the preferred cleavage site is between nucleotides 19 and 20, from the 5′ end of the 27-mer. A 
similar accumulation of products was observed for YpRNase E, BpRNase E and AbRNase E NTDs except that the 
11-mer and the 12-mer accumulated at the fastest rate for BpRNase E and AbRNase E NTDs, respectively. For 
FtRNase E NTD, the 12-mer accumulated significantly faster than the other cleavage products indicating that 
the preferred cleavage site is between nucleotides 15 and 16. Interestingly, after three minutes, the abundance of 
this cleavage product began to decline while the abundance of the trimer, pentamer and hexamer dramatically 
increased. This suggests that the initial 12-mer product can undergo a secondary cleavage to produce the shorter 
trimers, pentamers and hexamers.
Discussion
We have investigated the structural and biochemical properties of the NTD of four, previously uncharacterised, 
RNase E homologues from bacterial pathogens and compared them to those of the well-characterised NTD from 
E. coli RNase E. Fundamentally, these NTDs are highly conserved at the sequence level and, as might have been 
expected, they have similar properties in that they are all homotetrameric, endoribonucleases. However, there 
are also subtle differences between them. The NTD from RNase E from B. pseudomallei is predicted to adopt a 
more closed conformation than the other RNase E NTDs (Fig. 3 and Supplementary Table S2) while the substrate 
specificity of F. tularensis RNase E NTD differs from the other RNase E NTDs (Figs 4 and 5).
Three principle regions of sequence variability were identified in the RNase E NTDs, amino acids 175–203, 
233–263 and 457–508 (Fig. 1). Despite this sequence variability, the structure of these regions is predicted to be 
conserved (Figs 2 and S2). Two of these regions, one in the 5′ sensor domain (amino acids 175–203) and one 
in the RNase H domain (amino acids 233–263), are located at the peripheral edges of the tetrameric protein 
structure (Supplementary Fig. S2). These regions have no known direct catalytic function; however, given their 
location, it is possible that they may play a structural role in the movement of the 5′ sensor and S1 domains during 
the transition from an open to a closed conformation upon substrate binding. Interestingly, in solution, the RNase 
E NTD from B. pseudomallei adopts a more closed conformation than the other four RNase E NTDs (Fig. 3 and 
Supplementary Table S2) which could be related to the divergent sequence in this region. The third region of 
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Figure 5. Cleavage site specificity of RNase E NTDs. (ai) Schematic of the target-guide RNA substrate. 
Coloured arrows indicate the position of cleavage sites that were observed for at least one of the RNase E NTDs, 
with the numbers above the arrows indicating the length of the 3′ FAM-labelled product that is produced by 
cleavage at that position. The cleavage sites that were observed for each homologue are indicated by stars above 
the respective position. (aii) 20% urea-PAGE analysis of cleavage of 1 μM target-guide substrate by 5 nM E. coli, 
Y. pestis, F. tularensis, B. pseudomallei or A. baumannii RNase E NTD after incubation at 28 °C for 10 minutes. 
The gel was visualised using a G:Box UV transilluminator (Syngene). The gel in this figure has been cropped and 
the uncropped gel is presented in Supplementary Fig. S6a. The band corresponding to the FAM-labelled 27-mer 
component of the target-guide substrate is labelled and the coloured arrows to the right of the gel correspond 
to the FAM-labelled cleavage products described in ai. (b) 20% urea-PAGE analysis of cleavage of 1 μM target-
guide substrate by 5 nM E. coli, Y. pestis, F. tularensis, B. pseudomallei or A. baumannii RNase E NTD at 28 °C 
during a 10-minute time course. Gels were visualised using a G:Box UV transilluminator. The gels have been 
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sequence variability, in the small domain (amino acids 457–508), is located at the protomer-promoter interface 
(Supplementary Fig. S2), where amino acid substitutions could affect tetramerisation. However, all five RNase 
E NTDs appear to be homotetrameric in solution (Supplementary Table S1), suggesting that the function of the 
small domain is conserved.
All of the RNase E NTDs investigated endoribonucleolytically cleaved model RNA substrates (Figs 4 and 5). 
This was not surprising given that the key residues known to be involved in RNA cleavage at the active site are 
absolutely conserved (Fig. 1). This study utilised model RNA substrates that we would expect to be cleaved via a 5′ 
end-dependent mechanism in which a 5′ monophosphate is specifically recognised by the 5′ sensor pocket18,23,31. 
The key residues known to be required for discriminating substrates with a 5′ monophosphate within this pocket 
are absolutely conserved in the RNase E NTDs investigated and, not surprisingly, all of the RNase E NTDs showed 
a preference for a 5′ monophosphorylated substrate (Fig. 4). However, more complex natural substrates such as 
9S RNA, the precursor of 5S rRNA, can also be cleaved through an internal entry mechanism which relies on 
the recognition of a stem loop structure upstream of the cleavage site33–35. A recent study identified eight amino 
acids (Arg3, Gln22, His268, Tyr269, Gln270, Lys433, Arg488 and Arg490) in the E. coli RNase E NTD domain that are 
important for recognition of the stem loop25. These residues are absolutely conserved in Y. pestis RNase E but 
there are substitutions at two of the positions in B. pseudomallei and at six of the positions in F. tularensis and A. 
baumannii RNase Es. It remains to be seen whether these substitutions affect RNA cleavage through the internal 
entry mechanism for these RNase Es. Finally, substrate cleavage patterns varied between the RNase E NTDs, 
with the most striking differences observed for F. tularensis RNase E (Fig. 5), hinting at possible differences in the 
reaction mechanism.
In conclusion, we have characterised the RNase E NTD homologues from Y. pestis, F. tularensis, A. baumannii 
and B. pseudomallei. This is the first demonstration that these RNase E NTDs have endoriboucleolytic activity. 
Furthermore, through a comparison with EcRNase E NTD, we have shown that, despite the expected global struc-
tural and catalytic similarities, there are also subtle species-specific differences between them. These observed 
subtle differences would not have been predicted de novo from amino acid sequence. The most significant dif-
ferences were identified in two of the RNase E NTDs with the lowest sequence similarity, B. pseudomallei and F. 
tularensis. However, B. pseudomallei RNase E NTD varied in its structural properties while F. tularensis RNase E 
NTD varied in its biochemical properties. It remains to be determined, how significant these differences prove 
to be, but it does suggest caution when applying generalities based on studies with model organisms. In terms of 
the development of antibacterial drugs targeting RNase E, it has already been reported that RNase Es from differ-
ent species respond differently to compounds selected based on inhibition of RNase E from E. coli13. Therefore, 
these subtle differences may prove to be critical when designing antibacterial approaches targeting RNase E in 
pathogens.
Methods
protein sequence alignment. RNase E amino acid sequences were downloaded from UniProtKB using 
the following accession codes: EcRNase E (P21513), YpRNase E (Q74TC3), FtRNase E (Q5NFK7), BpRNase E 
(A0A0H3HN63) and AbRNase E (A0A0B9WR03). The sequences were aligned in MOE (Molecular Operating 
Environment, 2013.08; Chemical Computing Group Inc., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, 
Canada, H3A 2R7) using the default parameters, including a BLOSUM62 substitution matrix. This alignment was 
used to define the catalytic NTD for each of the RNase Es as the amino acids that aligned with amino acids 1–529 
of EcRNase E. Sequences were then trimmed to the NTD boundaries and the similarity of each homologue to 
EcRNase E NTD was calculated in MOE.
RNase e NtD homology models. RNase E NTD homology models were generated for YpRNase E, 
FtRNase E, BpRNase E and AbRNase E in MOE using the sequences that had been trimmed to the NTD bounda-
ries (Fig. 1), EcRNase E NTD crystal structures as the template structure (2BX218 for the closed conformation and 
2VMK26 for the open conformation) and the default settings. Ten initial modes were produced and averaged to 
give the most energetically favourable model. The RMSD between each model and the template EcRNase E NTD 
structure was calculated in MOE.
Cloning of RNase e NtD expression strains. RNase E NTDs were cloned into the pET16b expres-
sion plasmid (Novagen), in order to express them as N-terminally His10-tagged proteins. EcRNase E NTD (aa 
1–529) cloned into pET16b, was kindly provided by Prof. Ben Luisi (University of Cambridge, UK). The cod-
ing sequences for the RNase E NTDs were obtained from the European Nucleotide Archive: YpRNase E (aa 
1–529; CAL20235.1), FtRNase E (aa 1–543; KFJ71366.1), BpRNase E (aa 1–532; EET07304.1), and AbRNase E (aa 
1–544; A0A0B9WR03). The genes were codon-optimised in silico using GeneOtimizer® software (GeneArt, Life 
Technologies), synthesised by GeneArt and ligated between the NdeI and BamHI restriction sites of pET16b. All 
constructs were confirmed by DNA sequencing and E. coli BL21(DE3)pLysS was transformed with the plasmids 
for protein expression.
cropped and the uncropped gels are presented in Supplementary Fig. S6b. Coloured arrows to the right of the 
gels correspond to the cleavage positions depicted in ai. Graphs show the percentage of the FAM-labelled 27-
mer component of the target-guide substrate and each of the FAM-labelled cleavage products at each time point 
for the entire time course (left) and the first minute of the time course (right). Data are the average of three 
experiments and error bars represent the standard deviation.
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protein expression. RNase E NTD expression strains were grown in 500 ml LB supplemented with 100 μg/
ml ampicillin, at 37 °C, with shaking (250 rpm), until the OD600 reached 0.6. Recombinant protein expression was 
induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and 
cells were incubated for a further 3 hours, at 37 °C, with shaking. Cells were harvested by centrifugation at 7,000 
rcf and 4 °C for 20 minutes and stored at −20 °C.
Protein purification. All RNase E NTDs were purified essentially as described previously for EcRNase E 
NTD19. Briefly, frozen cell pellets were thawed on ice and resuspended in 50 ml of lysis buffer (20 mM Tris-HCl 
pH 8, 500 mM NaCl and 20 mM imidazole) supplemented with a cOmpleteTM ethylenediaminetetraacetic acid 
(EDTA)-free protease inhibitor cocktail tablet (Roche). Cells were lysed by sonication for 10 minutes (3.3 seconds 
on, 9.9 seconds off) using a Sonics Vibra Cell VCX 500 sonicator. Each lysate was clarified by centrifugation at 
40,000 g, at 4 °C, for 20 minutes and was subsequently loaded onto a 5 ml HisTrap FF column (GE Healthcare) 
equilibrated in lysis buffer using an ÄKTA Purifier (GE Healthcare). Bound proteins were eluted with a linear gra-
dient from 20 to 500 mM imidazole (0 to 100% elution buffer (20 mM Tris pH 8, 500 mM NaCl and 500 mM imi-
dazole)) applied over six column-volumes. Fractions containing RNase E NTD were pooled and buffer-exchanged 
into storage buffer (20 mM Tris pH 8, 500 mM NaCl, 10 mM MgCl2, 10 mM EDTA, 10 mM dithiothreitol (DTT) 
and 10% (v/v) glycerol) using a HiPrep 26/10 Desalting column (GE Healthcare) and an ÄKTA Purifier. RNase 
E NTD was concentrated using a Vivaspin 20 centrifugal concentrator with a molecular weight cut-off (MWCO) 
of 10 kDa (Sartorius) and loaded onto a HiLoad 16/600 Superdex 200 prep grade size-exclusion column (GE 
Healthcare) equilibrated in storage buffer using an ÄKTA Purifier. Fractions containing RNase E were pooled, 
concentrated using a Vivaspin 20 (MWCO 10 kDa) centrifugal concentrator and stored at −80 °C. The size and 
homogeneity of the purified RNase E NTDs was assessed by 12% SDS-PAGE. The identity of the purified protein 
was confirmed by liquid chromatography tandem mass spectroscopy (LC-MS-MS; Astbury Centre, University 
of Leeds, UK).
size-exclusion chromatography coupled small-angle x-ray scattering (seC-sAXs). SEC-SAXS 
experiments were performed at the B21 beamline at the Diamond Light Source (DLS, Didcot, UK). RNase E 
NTDs were concentrated using a Vivaspin 20 (MWCO 10 kDa) centrifugal concentrator to a concentration of 
5–10 mg/ml in sample buffer (10 mM DTT, 10 mM MgCl2, 0.5 M NaCl, 20 mM Tris (pH 8)). 45 μl were loaded 
onto a 4.6 ml KW403–4F size-exclusion column (Showdex) equilibrated in sample buffer at a flow rate of 0.1 ml/
min, using an Agilent 1260 HPLC system. SAXS data were collected at 3-second intervals, at a wavelength of 12.4 
KeV and a fixed camera length of 4.014 m using a Pilatus 2 M photon counting detector (Dectris), for 32 minutes. 
The data were normalised to the intensity of the incident beam and the scattering from the buffer was subtracted 
using an in-house program. Further data processing was then performed with the ATSAS suite36. PRIMUS37 was 
used to calculate the Rg and forward scattering intensity (I(0)) for the RNase E NTDs. I(0) was used to calculate 
the molecular weight (MW). The distance distribution function p(R) was generated with GNOM38 and was used 
to determine the Dmax. For EcRNase E NTD 20 ab initio models were generated in DAMMIF39 and averaged in 
DAMAVER40. Crystal structures for EcRNase E NTD in a closed conformation (2BX2;18), open conformation 
(2VMK;26) and a transitioning conformation (5F6C;25) were fitted to the averaged model using CHIMERA41. The 
theoretical scattering, based on the crystal structures, for EcRNase E NTD in each of these three conformations 
was compared to the experimental scattering for each RNase E NTD in CRYSOL42.
RNase e discontinuous assay. Discontinuous RNase E assays were carried out using one of three 
model RNA substrates: 5′ phosphorylated, 3′ FAM-labelled UUU ACA GUA UUU G (5′-p-RNA13-FAM-3′) 
13-mer18,31; 5′ hydroxylated, 3′ FAM-labelled UUU ACA GUA UUU G (5′-OH-RNA13-FAM-3′) 13-mer or a 
partially double-stranded substrate (target-guide;32) generated by annealing a 5′ 4-(4-dimethylaminophenyl) 
diazenylbenzoic acid (DABCYL)-labelled, 3′ FAM-labelled GGA UCG GAG UUU UAA AUU AAU AAU AUA 
27-mer and a 5′ phosphorylated UUU UCU CCG AUC C 13-mer at 28 °C for 15 minutes. The labelled 27-mer 
and unlabeled 13-mer were annealed at a ratio of 1:1.14 to ensure that all of the labelled 27-mer was partially 
double-stranded. All RNAs were obtained from Dharmacon. 30 μl reaction mixtures containing 1.25 to 5 nM 
RNase E NTD (see Figure legends for details), 1 μM substrate (see Figure legends for details), 25 mM Tris pH 8, 
100 mM NaCl, 15 mM MgCl2, 1 mM DTT, 37.5 mg/ml Ficoll 70 and 5% (v/v) dimethyl sulfoxide (DMSO) were 
incubated at 28 °C for the indicated time(s). Reactions were terminated by the addition of 0.5 volumes of quench 
buffer (95% (v/v) formamide, 20 mM EDTA) and reaction products were resolved by denaturing 7.5 M urea 20% 
PAGE. Gels were visualised using a G:Box UV transilluminator (Syngene) and, where indicated, quantified by 
densitometry using ImageJ (Rasband WS, ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997–2016).
Data Availability
SAXS data have been deposited at SASBDB under Accession Codes SASDE52, SASDE62, SASDE72, SASDE82 
and SASDE92.
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